Clinical and analytical performance of the onclarity HPV assay using the valgent framework

Journal of Clinical Microbiology

Volumn 53, Issue 10, 2015, Pages 3272-3279

  Cuschieri, K ^a   Geraets, D T ^b   Moore, C ^a   Quint, W ^b   Duvall, E ^a   Arbyn, M ^c  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b DDL DIAGNOSTIC LABORATORY   (Netherlands)

^c SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ARTICLE; DEMOGRAPHY; DISEASE SEVERITY; ENZYME IMMUNOASSAY; FEMALE; GENOTYPE; GENOTYPING TECHNIQUE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; MAJOR CLINICAL STUDY; NONHUMAN; ONCLARITY ASSAY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CARCINOMA IN SITU; VIRUS DETECTION; WART VIRUS; ADOLESCENT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLASSIFICATION; COMPLICATION; EARLY CANCER DIAGNOSIS; EVALUATION STUDY; GENETICS; ISOLATION AND PURIFICATION; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROCEDURES; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; EARLY DETECTION OF CANCER; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84941947351     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01366-15     Document Type: Article

References (27)

1. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J. 2012. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 30(Suppl 5):F88-F99.
2. Tabrizi SN, Brotherton JM, Kaldor JM, Skinner SR, Liu B, Bateson D, McNamee K, Garefalakis M, Phillips S, Cummins E, Malloy M, Garland SM. 2014. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 14:958-966. http://dx. doi. org/10 . 1016/S1473-3099(14)70841-2.
3. Poljak M, Cuzick J, Kocjan BJ, Iftner T, Dillner J, Arbyn M. 2012. Nucleic acid tests for the detection of alpha human papillomaviruses. Vaccine 30(Suppl 5):F100-F106.
4. Cubie HA, Cuschieri K. 2013. Understanding HPV tests and their appropriate applications. Cytopathology 24:289-308.
5. Ejegod DM, Serrano I, Cuschieri KS, Nussbaumer WA, Vaughan LM, Ahmad AS, Cuzick J, Bonde J. 2013. Clinical validation of the BD Onclarity HPV assay using a non-inferiority test. J Med Microbiol Diagn S3:003. http://dx. doi. org/10. 4172/2161-0703. S3-003.
6. Wright TC, Jr, Stoler MH, Sharma A, Zhang G, Behrens C, Wright TL. 2011. Evaluation of HPV-16 and HPV-18 genotyping for the triage of women with high-risk HPV-cytology-negative results. Am J Clin Pathol 136:578-586. http://dx. doi. org/10. 1309/AJCPTUS5EXAS6DKZ.
7. Cox JT, Castle PE, Behrens CM, Sharma A, Wright TC, Jr, Cuzick J. 2013. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study. Am J Obstet Gynecol 208: 184. e1-184. e11.
8. Schiffman M, Burk RD, Boyle S, Raine-Bennett T, Katki HA, Gage JC, Wentzensen N, Kornegay JR, Aldrich C, Tam T, Erlich H, Apple R, Befano B, Castle PE. 2015. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol 53:52-59. http://dx. doi. org/10. 1128/JCM . 02116-14.
9. Arbyn M, Schneider A, Gissmann L, Kaufmann AM. 2012. Highlights of the 27th International Papillomavirus Conference and Clinical Workshop: part 2: applied clinical science. Future Virol 7:19-24. http://dx. doi . org/10. 2217/fvl. 11. 131.
10. Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, Pawlita M. 2013. Prevalence and viral load of 51 genital human papillomavirus types and three subtypes. Int J Cancer 132:2395-2403. http://dx. doi. org /10. 1002/ijc. 27891.
11. Geraets DT, Cuschieri K, de Koning MN, van Doorn LJ, Snijders PJ, Meijer CJ, Quint WG, Arbyn M. 2014. Clinical evaluation of a GP5-/ 6based Luminex assay having full high-risk human papillomavirus genotyping capability and an internal control. J Clin Microbiol 52:3996-4002. http://dx. doi. org/10. 1128/JCM. 01962-14.
12. Arbyn M, Snijders PJ, Meijer CJ, Berkhof H, Cuschieri K, Kocjan BJ, Poljak M. 2015. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening? Clin Microbiol Infect http://dx. doi. org /10. 1016/j. cmi. 2015. 04. 015.
13. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ. 2009. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 124:516-520. http://dx. doi. org/10. 1002/ijc. 24010.
14. van den Brule AJ, Meijer CJ, Bakels V, Kenemans P, Walboomers JM. 1990. Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol 28:2739-2743.
15. Cuzick J. 1985. A Wilcoxon-type test for trend. Stat Med 4:87-90. http: //dx. doi. org/10. 1002/sim. 4780040112.
16. Smith JHF, Patnick J (ed). 2013. Achievable standards, benchmarks for reporting, and criteria for conducting cervical cytopathology, 2nd ed. NHS Cancer Screening Programmes, Sheffield, United Kingdom. http: //www. cancerscreening. nhs. uk/cervical/publications/nhscsp01. html.
17. Luesley D, Leeson S (ed). 2010. Colposcopy and programme management, 2nd ed. NHS Cancer Screening Programmes, Sheffield, United Kingdom. http://www. cancerscreening. nhs. uk/cervical/publications/nhscsp20. html.
18. Hirschowitz L (ed). 2012. Histopathology reporting in cervical screening: an integrated approach, 2nd ed. NHS Cancer Screening Programmes, Sheffield, United Kingdom. http://www. cancerscreening. nhs. uk/cervical /publications/cc-04. html.
19. Tang NS, Tang ML, Chan IS. 2003. On tests of equivalence via non-unity relative risk for matched-pair design. Stat Med 22:1217-1233. http://dx . doi. org/10. 1002/sim. 1213.
20. Arbyn J, Tommasino M, Depyudt C, Dillner J. 2014. Are 20 human papillomavirus types causing cervical cancer. J Pathol 234:431-435. http: //dx. doi. org/10. 1002/path. 4424.
21. Arbyn M, Verdoodt F, Snijders PJF, Verhoef VM, Suonio E, Dillner J, Minozzi S, Bellisario C, Banzi R, Zhao FH, Hillemanns P, Anttila A. 2014. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol 15:172-183. http://dx. doi. org/10. 1016/S1470-2045(13)70570-9.
22. Kavanagh K, Pollock KG, Potts A, Love J, Cuschieri K, Cubie H, Robertson C, Donaghy M. 2014. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 110:2804-2811. http://dx. doi. org/10. 1038/bjc. 2014. 198.
23. Cuschieri K, Cubie H, Graham C, Rowan J, Hardie A, Horne A, Earle CB, Bailey A, Crosbie EJ, Kitchener H. 2014. Clinical performance of RNA and DNA based HPV testing in a colposcopy setting: influence of assay target, cut off and age. J Clin Virol 59:104-108. http://dx. doi. org/10 . 1016/j. jcv. 2013. 12. 001.
24. Wright TC, Jr, Stoler MH, Agreda PM, Beitman GH, Gutierrez EC, Harris JM, Koch KR, Kuebler M, LaViers WD, Legendre BL, Jr, Leitch SV, Maus CE, McMillian RA, Nussbaumer WA, Palmer ML, Porter MJ, Richart GA, Schwab RJ, Vaughan LM. 2014. Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens. Am J Clin Pathol 142:43-50. http://dx . doi. org/10. 1309/AJCP53KMHNRDICBL.
25. Rebolj M, Preisler S, Ejegod DM, Rygaard C, Lynge E, Bonde J. 2014. Disagreement between human papillomavirus assays: an unexpected challenge for the choice of an assay in primary cervical screening. PLoS One 9:e86835. http://dx. doi. org/10. 1371/journal. pone. 0086835.
26. Castle PE, Porras C, Quint WG, Rodriguez AC, Schiffman M, Gravitt PE, Gonzalex P, Katki HA, Silva S, Freer E, Van Doorn LJ, Jimenez S, Herrero R, Hildesheim A. 2008. Comparison of two PCR-based human papillomavirus genotyping methods. J Clin Microbiol 46:3437-3445. http://dx. doi. org/10. 1128/JCM. 00620-08.
27. Castle PE, Solomon D, Hildesheim A, Herrero R, Concepcion Bratti M, Sherman ME, Cecilia Rodriguez A, Alfaro M, Hutchinson ML, Terence Dunn S, Kuypers J, Schiffman M. 2003. Stability of archived liquid-based cervical cytologic specimens. Cancer 99:89-96.